Otsuka Seeks Re-Examination Of Abilify Patent Due To Error In Original Filing
Japanese drug maker Otsuka Pharmaceutical Co. has filed a request with the U.S. Patent and Trademark Office for a re-examination of the basic U.S. composition of matter patent covering Abilify (aripiprazole),...To view the full article, register now.
Already a subscriber? Click here to view full article